MARKET

ALPMY

ALPMY

Astellas Pharma
OTCPK
17.12
-0.03
-0.17%
Closed 15:51 11/20 EST
OPEN
17.35
PREV CLOSE
17.15
HIGH
17.35
LOW
17.12
VOLUME
7.50K
TURNOVER
129.28K
52 WEEK HIGH
17.38
52 WEEK LOW
11.71
MARKET CAP
30.70B
P/E (TTM)
12.45
1D
5D
1M
3M
1Y
5Y
1D
Bank of America Securities Sticks to Their Buy Rating for Astellas Pharma (ALPMF)
TipRanks · 1d ago
Weekly Report: what happened at ALPMY last week (1109-1113)?
Weekly Report · 4d ago
AstraZeneca gains additional bladder cancer indication for Imfinzi
Seeking Alpha · 11/13 21:23
Weekly Report: what happened at ALPMY last week (1102-1106)?
Weekly Report · 11/09 09:23
Astellas Pharma (ALPMF) Receives a Hold from Morgan Stanley
TipRanks · 11/05 10:06
Astellas Pharma (ALPMF) Receives a Buy from Macquarie
TipRanks · 11/05 10:05
Astellas Pharma ADR GAAP EPS of v134.47, revenue of ¥1270.86B; updates FY2027 outlook
Seeking Alpha · 11/04 07:38
Here are the major earnings before the open Wednesday
Seeking Alpha · 11/03 23:00
More
About ALPMY
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Webull offers Astellas Pharma Inc stock information, including OTCPK: ALPMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPMY stock methods without spending real money on the virtual paper trading platform.